Objective: To explore the value of edaravone in improving cerebral blood flow, alleviating oxidative stress damage and reducing nerve defect in patients with acute ischemic stroke. Methods: A total of 112 patients with acute ischemic stroke in our department from March 2023 to June 2024 were selected as the study subjects. 56 patients in the control group were given routine intravenous thrombolysis therapy, and 56 patients in the observation group were treated with Edaravone dextrocamphorol. Inflammatory factor indexes, oxidative stress level, cerebral blood flow status, nerve defect degree and adverse reactions were compared between the two groups. Results: After 2 weeks of treatment, reduced glutathione and superoxide dismutase were increased in both groups (P<0.05), and higher in the observation group (P<0.05), and malondialdehyde was decreased in both groups (P<0.05), and lower in the observation group (P<0.05). The inflammatory factor indexes in both groups were decreased (P<0.05), and the observation group was lower (P<0.05). The maximum blood flow velocity and average blood flow velocity were increased in both groups (P<0.05), and higher in observation group (P<0.05). The score of nerve defect degree was lower in both groups (P<0.05), and lower in observation group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The application of edaravone in the treatment of acute ischemic stroke can increase cerebral blood flow, relieve oxidative stress damage, and reduce inflammatory factors and nerve defect.